Biopharma services company Allucent has announced that it has named Katy Moore to lead a team of pharmacometricians to create custom modeling and simulation approaches for clinical trial designs.
Moore’s official title will be president of clinical pharmacology, modeling and simulation (CPMS).
“What inspired me to join Allucent was the opportunity to work for a global company with comprehensive drug development expertise across a variety of therapeutic areas where, in collaboration with our partners, we can improve efficiency in the drug development process,” Moore said. “By optimizing strategies and providing evidence to answer development questions we can impact decisions at every stage and ultimately bring new therapies to patients faster.”
Moore has more than 25 years of experience in the pharma industry, holding senior positions at ViiV Healthcare and GSK. She worked at the latter company for 19 years.
Katy Moore, PharmD, RPh, President of Clinical Pharmacology, Modeling and Simulation (CPMS), Allucent
At ViiV Healthcare, she served as the global head of clinical pharmacology. She also founded and co-chaired the ViiV Healthcare Protocol Review Forum for Phase 1 to Phase 2a studies and launched an internship program.
At GSK, Moore presided over the viral diseases and oncology CPMS teams.
Moore earned a Pharm.D. degree from the University of North Carolina at Chapel Hill School of Pharmacy.
In her new role, Moore aims to “provide valued clinical pharmacology expertise and model-informed approaches that integrate drug disposition, pharmacology, disease outcomes, and patient diversity to optimize the dose, trial design, development plan, and regulatory strategy with our internal and external partners.”
“Katy brings a breadth and depth of experience that will have immense value for our team and our partners,” said Dr. Mark A. Goldberg, chairman and CEO of Allucent, in a press release. “Her expertise is of particular importance at this time when data-backed, biologically plausible modeling and simulation approaches can help avoid costly trials and support successful regulatory applications.”
Catering to small and mid-sized biotech companies, Allucent was formerly known as Cato SMS.
Filed Under: Drug Discovery and Development, Women in Pharma and Biotech
